Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’-Reference-Cited by-同舟云学术

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

Published:2018-05 Issue: Volume:94 Page:95-103
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Haas M.,Siveke J.T.,Schenk M.,Lerch M.M.,Caca K.,Freiberg-Richter J.,Fischer von Weikersthal L.,Kullmann F.,Reinacher-Schick A.,Fuchs M.,Kanzler S.,Kunzmann V.,Ettrich T.J.^ORCID,Kruger S.,Westphalen C.B.,Held S.,Heinemann V.,Boeck S.

Funder

Roche

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res,2014

2. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030;Quante;Cancer Med,2016

3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

4. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest Oncology Group-directed intergroup trial S0205;Philip;J Clin Oncol,2010

5. Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study;Safran;Am J Clin Oncol,2011

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zielgerichtete Therapie des Pankreaskarzinoms;Gastro-News;2024-06

2. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group;ESMO Open;2024-04

3. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial;European Journal of Cancer;2024-04

4. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?;Clinical and Translational Oncology;2023-10-04

5. Zielgerichtete Therapie des Pankreaskarzinoms;Die Onkologie;2023-07-20